Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01855945 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.
A Phase 1 study, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 1
- Development phase
- 627
- Enrollment target
NCT01855945: Completed Phase 1 study, sponsored by Novartis Vaccines.
NCT01855945 is a Phase 1 study that has completed, run by Novartis Vaccines. The registered enrollment target is 627 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (945% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01855945, a Phase 1 study, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 627 participants
- Enrollment target
Study Summary
Evaluate the safety and immunogenicity of three dosage levels of swine influenza vaccine in children ages 3 to \<9 years, adolescents 9 to \<18 years, adults 18 to \<65 years and elderly 65 years and older.
Primary Outcome
Safety and tolerability of H3N2 monovalent vaccine was assessed in terms of the number of subjects (3 to \<9 years of age) reporting solicited local and systemic adverse events and other adverse events after each vaccination.
Interventions
- BIOLOGICAL Swine Influenza
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 627 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
What the finished NCT01855945 record still lists
NCT01855945 is an interventional study that assigns participants to a tested intervention. The registered 627 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (945% higher).
The record links to 0 conditions, and to 1 intervention - of which Swine Influenza is the first listed.
NCT01855945 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01855945 about?
NCT01855945 is a clinical study titled "Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.". Evaluate the safety and immunogenicity of three dosage levels of swine influenza vaccine in children ages 3 to \<9 years, adolescents 9 to \<18 years, adults 18 to \<65 years and elderly 65 years and older.
What is the current status of trial NCT01855945?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 627 participants. The study started on 2013-05. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01855945?
The interventions under investigation include: Swine Influenza (BIOLOGICAL).
Who is sponsoring clinical trial NCT01855945?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01855945's enrollment target sits among peer trials
627 23rd of 2000 higher than 1,978 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06040827 · 626 participants
A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia